Therapeutic Vulnerabilities in DIPG and pHGA

We are using high throughput drug screens and CRISPR screens to identify potential drugs or pathways that show synthetic lethality with the histone mutations. In addition, we are using multi-omics approaches and protein interactome data to identify proteins and pathways which are altered in the context of mutant histones.



Mailing Address

Arthur and Sonia Labatt Brain Tumour Research Centre

The Hospital for Sick Children

Peter Gilgan Centre for Research and Learning

686 Bay Street, 17-9702
Toronto, ON  M5G 0A4